Two executives of Fosun Group resigned on one day. The company's 2017 target is 16.6 billion revenue!

Liang Xinjun, one of the "four swordsmen" of Fosun Group, resigned naked, while song Jinsong, senior vice president of Fosun Pharmaceutical, also resigned on the same day, but what about the resignation of senior executives? The new target of Fosun Pharmaceutical, which just released the 2016 financial report, is to achieve 16.6 billion yuan in 2017 What is the secret of Fosun Pharmaceutical's high growth? How to achieve this goal? On March 28, two screen swiping events happened in Fosun Group's circle of friends Liang Xinjun, the vice chairman and CEO of Fosun Group's "four swordsmen", gave a "naked speech", while Fosun Group's 2016 financial report was widely concerned by medical people In fact, in addition to the above two events, Fosun Pharmaceutical also has the change of people worthy of attention The first is that Chen Qiyu, who is in charge of the medical and health field of Fosun Group, has been appointed as the contact president of Fosun Group, and this personnel change is believed that Fosun Group will increase its development in the field of health The other thing that is less concerned by the media is that the board of directors of Fosun Pharmaceutical received a written resignation letter from Song Jinsong, who applied to the board of directors of the company for resignation due to personal reasons and no longer held the post of senior vice president of Fosun Pharmaceutical since March 28 Although executive turnover is a significant event for listed companies, it does not affect the rapid development of Fosun Pharmaceutical's performance According to the annual report of Fosun Pharmaceutical, in 2016, the revenue was RMB 14 billion 629 million, with a year-on-year growth of 16.02% The net profit attributable to shareholders of the listed company was RMB 2 billion 806 million, with a year-on-year growth of 14.05% In the past decade, Fosun Pharmaceutical has achieved a compound annual growth rate of about 36% in the net profit index attributable to shareholders of listed companies after deducting non recurring profit and loss Fosun Pharmaceutical said that its two wheel drive strategy of "endogenous growth plus external expansion" ensures long-term and rapid performance growth Fosun medicine left the impression of an industry that it was "skilful in the capital field" However, if we study the logic behind it, it is not difficult to find that it snatched strategic resources through its rapid capital position Now Fosun Pharmaceutical is focusing on R & D resources and medical service resources 1 R & D acceleration in the business system of Fosun Pharmaceutical, it is mainly divided into drug R & D and manufacturing, medical devices and medical diagnosis and medical services The main segment is R & D and manufacturing, with revenue of 10.26 billion yuan in the past year, an increase of 14.83% over 2015 In addition, a total of 18 single products or series of preparations sold more than 100 million yuan, and sales of aldrin, util, Cefmetazole preparations, Atomolan and other products or series exceeded 500 million yuan In the past years of development, Fosun Pharmaceutical has always been M & A in the pharmaceutical industry However, the impression of a single industry is unclear as to the strength of R & D However, in 2016, Fosun's R & D investment (including capitalization) totaled 1.106 billion yuan, a year-on-year increase of 33.23% Among them, the R & D investment in the pharmaceutical manufacturing and R & D sector was 963 million yuan, an increase of 38.03% over 2015 The rapid growth of R & D investment of Fosun Pharmaceutical is accelerating the construction of its R & D capability In terms of R & D system building, Fosun Pharmaceutical has platforms such as Fuhong Hanlin, fuchuang, Xingtai, Chongqing Institute of medical technology, etc with global resources allocation, it conducts 24-hour joint R & D in Shanghai, Chongqing, Taipei and San Francisco, the United States It focuses on the R & D of small molecule chemical innovative drugs, large fraction biological similar drugs, high-value generic drugs and special preparations For R & D advantages, Wu Yifang, President of Fosun Pharmaceutical, told e pharmaceutical manager that first Fosun Pharmaceutical is unique in China in terms of industrial chain closed-loop After years of development, we have a clear understanding of the needs and can grasp the best growth opportunities; second Fosun Pharmaceutical has completed the international layout, and with Fosun international endorsement, Fosun Pharmaceutical can integrate international talents and talents Innovative resources make R & D more efficient In fact, from the development of Fosun medicine in the past years, we can see that its strategic implementation is more about seizing resources In the early stage of development, we entered the capital market very early, and then quickly made acquisitions to obtain excellent M & a target resources; we invested in Sinopharm holdings in the circulation field, and quickly took the resources with government background; now, Fosun Pharmaceutical began to seize the R & D resources, and its Fuhong Hanlin is widely concerned in the field of biological drug R & D, and currently we are researching six monoclonal antibody products Securities analysts have analyzed that trastuzumab developed by the company is likely to be the earliest listing among local enterprises In an interview with e-medicine managers, Wu Yifang said that with the help of international layout, Fosun medicine is still focusing on R & D and innovation, focusing on aging, newborn, sub-health, tumor and autoimmune diseases "We should take advantage of the innovation resources of the United States and combine the advantages of China to launch high-value innovative products." Strengthening R & D strength is also the main way to enter the international market In 2016, Fosun Pharmaceutical announced its plan to acquire 86.08% of the equity of Indian pharmaceutical company gland Pharma for us $126137 million (about 8.4 billion yuan) According to Wu Yifang, in the future, Fosun Pharmaceutical will mainly focus on the European and American markets, make full use of the European and American markets, Israel, Japan and other markets, combine with China, enrich the whole business chain, and form a real international competitiveness 2 accelerated investment in medical services in 2016, the growth rate of medical services reached 21.67%, ranking first in several business sectors According to the financial report, during the period, the company's holding medical service business realized a total revenue of 1.677 billion; excluding the impact of the newly established Wenzhou geriatric hospital and other companies this year, the revenue increased by 13.57% compared with the same caliber in 2015 In terms of medical layout, Fosun Pharmaceutical is speeding up in the past two years According to Wu Yifang, medical services account for 17% of GDP in the United States, while only about 6% in China, with a large growth space, which will be a good opportunity for Fosun Pharmaceutical to become a medical leader In terms of strategic implementation, Chen Qiyu, chairman of Fosun Pharmaceutical, once said: "the future layout of Fosun Pharmaceutical medical services is mainly aimed at the specialized and general hospitals in the second and third tier cities; meanwhile, we will continue to consolidate the construction of harmonious family hospitals in Beijing and Shanghai." Wu Yifang told e pharmaceutical managers that there are three major sectors in medical services The first is to build a high-end medical service brand with united family as the main brand Now, the layout has been realized in Beijing, Shanghai and Tianjin, while hospitals in Qingdao have been opened, and construction has begun in Guangzhou and Pudong, Shanghai; the second is the construction of comprehensive hospitals in second and third tier cities Fosun Pharmaceutical actively develops comprehensive hospitals through joint investment with large hospitals, acquisition of private hospitals or other hospitals; third, specialized hospitals, such as tumor and hemodialysis, will be Fosun Pharmaceutical opportunities Public information shows that in the first half of 2016 alone, Fosun Pharmaceutical participated in the second phase project of Qingdao shandaqilu hospital and the restructuring of medical industry of related medical institutions of xukuang group Wenzhou geriatric hospital invested has opened, and it also started to operate the hemodialysis service chain business through Hunan Jingren In addition, Fosun also invested in Jimin Tumor Hospital, Guangji hospital, Zhongwu hospital, Chancheng hospital, Taizhou Zhejiang East Hospital, etc As of the end of the reporting period, the company's holdings of Chancheng hospital, Jimin hospital, Guangji hospital, Zhongwu hospital, Wenzhou geriatric hospital and other approved beds totaled 3018 Compared with most enterprises, Fosun Pharmaceutical is good at seizing resources in the field of medical services and other fields, and is more able to turn these opportunities into real income In addition to the current eye-catching R & D resources and medical service resource card, Fosun medicine has also made great strides in the past year in terms of prospective resource layout such as artificial intelligence and accurate diagnosis and treatment For the 2017 target, Fosun Pharmaceutical said in its financial report that its revenue is no less than 16.6 billion yuan More detailed in-depth reports on Fosun medicine are on the way! Please pay attention!